| BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design W Farnaby, M Koegl, MJ Roy, C Whitworth, E Diers, N Trainor, D Zollman, ... Nature chemical biology 15 (7), 672-680, 2019 | 405 | 2019 |
| Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity S Imaide, KM Riching, N Makukhin, V Vetma, C Whitworth, SJ Hughes, ... Nature chemical biology 17 (11), 1157-1167, 2021 | 125 | 2021 |
| Highly selective PTK2 proteolysis targeting chimeras to probe focal adhesion kinase scaffolding functions J Popow, H Arnhof, G Bader, H Berger, A Ciulli, D Covini, C Dank, ... Journal of Medicinal Chemistry 62 (5), 2508-2520, 2019 | 122 | 2019 |
| A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo C Kofink, N Trainor, B Mair, S Wöhrle, M Wurm, N Mischerikow, MJ Roy, ... Nature Communications 13 (1), 5969, 2022 | 89 | 2022 |
| A facile synthesis of ligands for the von Hippel–Lindau E3 ligase C Steinebach, SA Voell, LP Vu, A Bricelj, I Sosič, G Schnakenburg, ... Synthesis 52 (17), 2521-2527, 2020 | 23 | 2020 |
| A beginner’s guide to PROTACs and targeted protein degradation A Ciulli, N Trainor The Biochemist 43 (5), 74-79, 2021 | 16 | 2021 |
| Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design W Farnaby, M Koegl, MJ Roy, C Whitworth, E Diers, N Trainor, D Zollman, ... Nature Chemical Biology 15 (8), 846-846, 2019 | 11 | 2019 |
| Trivalent PROTACs enhance protein degradation through cooperativity and avidity S Imaide, KM Riching, V Vetma, C Whitworth, SJ Hughes, N Trainor, ... | 6 | 2020 |
| Proteolysis targeting chimera (protacs) as degraders of smarca2 and/or smarca4 A Ciulli, D Christian, E Diers, W Farnaby, M Roy, S Steurer, N Trainor US Patent App. 17/285,491, 2021 | 2 | 2021 |
| Confounding factors in targeted degradation of short-lived proteins V Vetma, LC Perez, J Elias, A Stingu, A Kombara, T Gmaschitz, N Braun, ... bioRxiv, 2024.02. 19.581012, 2024 | 1 | 2024 |
| Targeting cancer with small molecule pan-KRAS degraders J Popow, W Farnaby, A Gollner, C Kofink, G Fischer, M Wurm, D Zollman, ... bioRxiv, 2023.10. 24.563163, 2023 | 1 | 2023 |
| N-Myristoyltransferase as a drug target: a (chemical) space odyssey A Bell Imperial College London, 2015 | 1 | 2015 |
| Trivalent PROTACs enhance protein degradation through cooperativity and avidity A Ciulli, S Imaide, K Riching, V Vetma, C Whitworth, S Hughes, N Trainor, ... | | 2020 |
| Structure-based PROTAC design demonstrates BAF complex ATPase vulnerabilities in cancer M Koegl, W Farnaby, C Whitworth, M Roy, E Diers, N Trainor, S Steurer, ... Cancer Research 79 (13_Supplement), 3849-3849, 2019 | | 2019 |
| Profiling the methylome targets of the histone lysine methyltransferase DOT1L N Trainor Imperial College London, 2017 | | 2017 |
